Silence Therapeutics plc Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019
Silence Therapeutics plc (SLNCF) reported Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 of 494.51 GBP/shares for the 12-month period ending 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 · last filed 2024-03-13
GBP/shares
| Period end | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 12 month | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 12 month as first filed |
|---|---|---|
| 2023-12-31 | 494.51 GBP/shares 20-F · filed 2024-03-13 | |
| 2022-12-31 | 2.42K GBP/shares 20-F · filed 2024-03-13 | |
| 2021-12-31 | 146.02 GBP/shares 20-F · filed 2024-03-13 | |
| 2020-12-31 | 5.00 GBP/shares 20-F · filed 2023-03-15 | 0.05 GBP/shares 20-F/A · filed 2021-04-29 |
| 2019-12-31 | 105.32 GBP/shares 20-F · filed 2022-03-17 | 1.05 GBP/shares 20-F/A · filed 2021-04-29 |
| 2018-12-31 | 1.10 GBP/shares 20-F/A · filed 2021-04-29 |
USD/shares
| Period end | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 12 month |
|---|---|
| 2023-12-31 | $18.50 20-F · filed 2024-03-13 |
| 2022-12-31 | $29.25 20-F · filed 2024-03-13 |